Wesana Health Holdings Inc
Change company Symbol lookup
Select an option...
WSNAF Wesana Health Holdings Inc
ZEUS Olympic Steel Inc
EJH E-Home Household Service Holdings Ltd
AMZN Amazon.com Inc
BGTTF Goat Industries Ltd
BRDS Bird Global Inc
GHM Graham Corp
DRMA Dermata Therapeutics Inc
VGAS Verde Clean Fuels Inc
CURV Torrid Holdings Inc
Go


Based in Canada
Company profile

Wesana Health Holdings Inc is a Canada-based life science company. The Company is engaged in development and delivery of psychedelic and naturally sourced therapies to treat traumatic brain Injury related depressive disorder, anxiety and migraines through drug development and predictive diagnostics. The Company is also engaged in care development through its therapies and patent-pending protocols, and in care delivery through activating a multidisciplinary, technology-supported clinical model. Its SANA-013 is a novel composition and method of use that provides sustained effects and benefit over time. The Company’s novel and proprietary depression treatment protocol that includes a single high dose of psilocybin followed by a maintenance regimen of a micro dose of psilocybin combined with cannabidiol, significantly reduced depressive behaviors in a validated animal model.

Closing Price
$0.036
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Heavy Day)
Volume:
19,050

10-day average volume:
19,346
19,050

NEO ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 6, 2023 in the Class Action Filed on Behalf of NeoGenomics, Inc. Shareholders

5:45 am ET January 24, 2023 (PR Newswire) Print

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of NeoGenomics, Inc. (NASDAQ: NEO) alleging that the Company violated federal securities laws.

Class Period: February 27, 2020 to April 26, 2022Lead Plaintiff Deadline: February 6, 2023No obligation or cost to you.

Learn more about your recoverable losses in NEO:https://www.kleinstocklaw.com/pslra-1/neogenomics-inc-loss-submission-form?id=35834&from=4

NeoGenomics, Inc. NEWS - NEO NEWS

CLASS ACTION CASE DETAILS: The filed complaint alleges that NeoGenomics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) defendants represented to investors that it had a "comprehensive menu" of cancer tests with "every kind of testing modality that you can use for cancer, including some of the fast-growing new ones, like next-generation sequencing," which positioned the Company as a "one-stop-shop" for pathologists and gave NeoGenomics "a competitive advantage" as a "go-to reference lab with a comprehensive menu for just about any kind of tests that you want to have done in cancer"; and (2) defendants represented that NeoGenomics could "leverage" the supposedly "fixed cost" structure of its business to improve profitability as revenue increased and touted the Company's "robust Compliance Program . . . to ensure compliance with the myriad of . . . laws, regulations and governmental guidance applicable to our business."

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in NeoGenomics you have until February 6, 2023 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU:If you purchased NeoGenomics securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the NEO lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link: https://www.kleinstocklaw.com/pslra-1/neogenomics-inc-loss-submission-form?id=35834&from=4.

ABOUT KLEIN LAW FIRM

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:J. Klein, Esq.535 Fifth Avenue4th FloorNew York City, NY 10017jk@kleinstocklaw.comTelephone: (212) 616-4899www.kleinstocklaw.com

https://c212.net/c/img/favicon.png?sn=NY94755&sd=2023-01-24

View original content:https://www.prnewswire.com/news-releases/neo-alert-the-klein-law-firm-announces-a-lead-plaintiff-deadline-of-february-6-2023-in-the-class-action-filed-on-behalf-of-neogenomics-inc-shareholders-301728962.html

SOURCE The Klein Law Firm

https://rt.newswire.ca/rt.gif?NewsItemId=NY94755&Transmission_Id=202301240545PR_NEWS_USPR_____NY94755&DateId=20230124

comtex tracking

COMTEX_423198980/1005/2023-01-24T05:45:11

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.